This protocol is judged by an institutional evaluation board, an impartial group that reviews any clinical trials involving people. If a research consists of a Plan I drug, after the board approves the protocol as moral, the scientists must make an application for an investigational new drug (IND) variety within the FDA.With all the doses packaged